Dissociation between Inhibition and Killing by Levofloxacin in Human Granulocytic Anaplasmosis
- 1 December 2006
- journal article
- case report
- Published by Mary Ann Liebert Inc in Vector-Borne and Zoonotic Diseases
- Vol. 6 (4) , 388-394
- https://doi.org/10.1089/vbz.2006.6.388
Abstract
Human granulocytic anaplasmosis (HGA) is a potentially fatal tick-borne infection caused by Anaplasma phagocytophilum. Treatment options are limited for this entity, with doxycycline being the drug of choice. Certain fluoroquinolones such as levofloxacin are active against A. phagocytophilum in vitro. We report a hospitalized patient with HGA who improved coincident with a 13-day course of levofloxacin therapy, but clinically and microbiologically relapsed 15 days after completion of treatment. Relapse of infection after levofloxacin therapy was reproduced in a severe combined immune-deficient (SCID) mouse infection model. Quinolone therapy should not be considered curative of HGA.Keywords
This publication has 30 references indexed in Scilit:
- Evaluation of Antibiotic Susceptibilities of Ehrlichia canis , Ehrlichia chaffeensis , and Anaplasma phagocytophilum by Real-Time PCRAntimicrobial Agents and Chemotherapy, 2004
- Antibiotic Susceptibilities of Anaplasma ( Ehrlichia ) phagocytophilum Strains from Various Geographic Areas in the United StatesAntimicrobial Agents and Chemotherapy, 2003
- DNA Gyrase-Mediated Natural Resistance to Fluoroquinolones in Ehrlichia sppAntimicrobial Agents and Chemotherapy, 2001
- Antimicrobial Susceptibility of Ehrlichia phagocytophilaAntimicrobial Agents and Chemotherapy, 2001
- The agent of Human Granulocytic Ehrlichiosis resides in an endosomal compartment.Journal of Clinical Investigation, 1998
- Human Granulocytic Ehrlichiosis: A Case Series from a Medical Center in New York StateAnnals of Internal Medicine, 1996
- Direct Cultivation of the Causative Agent of Human Granulocytic EhrlichiosisNew England Journal of Medicine, 1996
- Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infectionAntimicrobial Agents and Chemotherapy, 1994
- Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1990
- Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolonesAntimicrobial Agents and Chemotherapy, 1989